AkdÄ: ACE-Hemmer und Lungenkrebs: Kausalzusammenhang nach

Zusammenfassung

15 March 2019 Inspections, Human Medicines Pharmacovigilance and Committees Division Minutes of PRAC meeting on 11-14 February 2019 Chair: Sabine Straus – Vice-Chair: Martin Huber Health and safety information In accordance with the Agency’s health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in the minutes is considered commercially confidential or sensiti

Kerninformationen

f these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, the minutes are a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be ...

liveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone [phone] An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Introduction ...

................................................................................ 13 2.1.1. Fenspiride (NAP) - EMEA/H/A-107i/1480 .................................................................... 13 2.2. Ongoing procedures ..........................................................................

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen